Intracellular Signalling Proteins (Volume 116) (Advances in Protein Chemistry and Structural Biology, Volume 116)

Intracellular Signalling Proteins, Volume 116, presents an overview of the current developments in mechanisms of intracellular signaling and involvement of these mechanisms in the development of a number of disorders and diseases. Opportunities for targeting the intracellular signaling cascades for benefiting patients are also discussed, along with chapters that focus on Voices from the Dead: The Complex Language of Dead Cells, Nucleobindins and Encoded Peptides: From Cell Signalling to Physiology, Estrogen Receptor Signaling Mechanisms, Intracellular Signaling of the AMP-Activating Protein Kinase, the Relationship between Mitofusin 2 and Cancer, Molecular Signaling in Bone Cells: Regulation Cell Differentiation and Survival, and more.

• Describes advances in the discovery and application of therapeutics that target intracellular signaling mechanisms
• Targeted to a very wide audience of specialists, researchers and students
• Contains timely chapters written by well-renowned authorities in their field
• Includes a number of high quality illustrations, figures and tables

Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.